SCHEMBL693161

SCHEMBL693161

Cc1nc2c[c]ccc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
ALDH1A1 P00352 5/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 2/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47
GAA P10253 1/20 0.44
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.38
TDP1 Q9NUW8 2/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
LDHA P00338 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL693730 0.86 GAA (0.50) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL6972136 0.77 CASR (0.36)
SCHEMBL6092113 0.76 KMT2A (0.37) SMN1; SMN2ALDH1A1KMT2ANPSR1
SCHEMBL18230244 0.76 KDM4E (0.30) ALDH1A1NPC1RAB9AMAPTGAA
SCHEMBL3391407 0.76 RAB9A (0.43) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL18230453 0.76 HTT (0.47) SMN1; SMN2ALDH1A1NPC1RAB9ATP53
SCHEMBL6967203 0.76 NPC1 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL18230188 0.76 LDHA (0.41) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL5263973 0.74 RAB9A (0.40) SMN1; SMN2ALDH1A1NPC1RAB9ATP53
SCHEMBL19346042 0.74 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN claimed
US-11897880-B2 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-02-13 US claimed
US-20220389005-A1 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-12-08 US claimed
CN-113149885-A EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-07-23 CN claimed
EP-2970307-B1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2020-03-11 EP claimed
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-25 US claimed
US-10077261-B2 Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer JANSSEN PHARMACEUTICA NV (BE) 2018-09-18 US claimed
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 US claimed
EP-3294705-A1 EBNA1 INHIBITORS AND METHODS USING SAME The Wistar Institute Of Anatomy And Biology (US) 2018-03-21 EP claimed
EP-2892892-B1 IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2017-05-31 EP claimed
US-5977102-A INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; DR. KARL THOMAE GMBH (DE) 1999-11-02 US claimed
EP-0939627-A1 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1999-09-08 EP claimed
WO-1999025687-A1 AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 1999-05-27 WO claimed
EP-0896533-A4 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK INC (US) 1999-04-28 EP claimed
CN-1212696-A Pyrimido [5, 4-d ] pyrimidines, medicaments containing these compounds, their use and processes for their preparation THOMAE GMBH DR K (DE) 1999-03-31 CN claimed
EP-0896533-A2 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1999-02-17 EP claimed
EP-0885227-A1 PYRIMIDO 5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION Dr. Karl Thomae GmbH (DE) 1998-12-23 EP claimed
WO-1998005315-A1 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1998-02-12 WO claimed
WO-1997032882-A1 PYRIMIDO[5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION DR. KARL THOMAE GMBH (DE) 1997-09-12 WO claimed
WO-1997030677-A2 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1997-08-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897880-B2 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors F2, F13B, SERPINE1 SMN1; SMN2 4540/4885ALDH1A1 2124/4885NPC1 3733/4885
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME MLLT1, EBNA1BP2, MALT1 SMN1; SMN2 2354/4885ALDH1A1 3939/4885NPC1 525/4885
US-10035801-B2 Pyrazolo compounds and uses thereof KDM5A, KDM5C, KDM5B SMN1; SMN2 1532/4885ALDH1A1 1424/4885NPC1 2336/4885
US-10077261-B2 Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer FASN, PLIN1, FABP1 SMN1; SMN2 2272/4885ALDH1A1 197/4885NPC1 969/4885
US-20220389005-A1 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS F2, F13B, SERPINE1 SMN1; SMN2 4540/4885ALDH1A1 2124/4885NPC1 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.